|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
A Phase II, multicenter, multinational, randomized, double-blinded, placebo-controlled dose-finding study to evaluate the efficacy and safety of carbabenzpyride in the treatment of uncomplicated influenza A.Prospective, multicenter, multinational, randomized, double-blinded, placebo-controlled dose-finding study in parallel groups (Phase II)
100 项与 Farmak International Holding GmbH 相关的临床结果
0 项与 Farmak International Holding GmbH 相关的专利(医药)
100 项与 Farmak International Holding GmbH 相关的药物交易
100 项与 Farmak International Holding GmbH 相关的转化医学